Acceleron Pharma has started dosing patients in a Phase II clinical trial of its therapeutic candidate ACE-083 for the treatment of Charcot-Marie-Tooth disease (CMT) patients.

CMT is a neurological disorder characterised by muscle weakness, and ACE-083 is a locally acting muscle agent based on follistatin protein being developed to selectively enhance growth and strength in target muscles.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The two-part Phase II trial will assess the therapeutic candidate in patients with weakness in a lower leg muscle called tibialis anterior (TA) that is involved in raising the foot at the ankle.

Acceleron executive vice-president and chief medical officer Matthew Sherman said: “We designed our clinical development strategy for ACE-083 to explore its activity in diseases with weakness in specific muscles due to an underlying neurological or muscle disorder.

"We designed our clinical development strategy for ACE-083 to explore its activity in diseases with weakness in specific muscles due to an underlying neurological or muscle disorder."

“With Phase II trials now underway in both CMT and facioscapulohumeral muscular dystrophy, we will be able to evaluate ACE-083’s effect on both muscle strength and function across a range of neuromuscular diseases.”

See Also:

In the first open-label, dose-escalation part of the trial, safety and increases in muscle volume will be assessed in approximately 18 patients, following administration of ACE-083 injection into the TA muscle once every three weeks over a period of three months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s second randomised, double-blind, placebo-controlled part will evaluate an optimal dose level selected in the first part in up to 24 subjects over three months.

During this part, patients will be monitored for muscle volume, strength, function and safety.